KMT2D and chronic myelogenous leukemia, BCR-ABL1 positive: However, when we stratified the CML samples according to their different stages, MLL2/KMT2D showed a higher expression in chronic phase, with a gradually lower expression in the accelerated phase (twofold) reaching the lowest expression in the aggressive blast phase (fourfold) (Fig. 1b, Kruskal–Wallis test followed by Dunn’s Multiple Comparison test, p = 0.0415).